Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Net Cash Flow: 2019-2025

Historic Net Cash Flow for Kymera Therapeutics (KYMR) over the last 6 years, with Sep 2025 value amounting to -$222.9 million.

  • Kymera Therapeutics' Net Cash Flow fell 617.79% to -$222.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year decrease of 92.46%. This contributed to the annual value of $10.3 million for FY2024, which is 75.10% down from last year.
  • Per Kymera Therapeutics' latest filing, its Net Cash Flow stood at -$222.9 million for Q3 2025, which was down 190.66% from $245.9 million recorded in Q2 2025.
  • In the past 5 years, Kymera Therapeutics' Net Cash Flow registered a high of $245.9 million during Q2 2025, and its lowest value of -$222.9 million during Q3 2025.
  • Moreover, its 3-year median value for Net Cash Flow was $1.9 million (2023), whereas its average is $4.0 million.
  • Per our database at Business Quant, Kymera Therapeutics' Net Cash Flow surged by 1,227.40% in 2021 and then plummeted by 1,470.87% in 2024.
  • Over the past 5 years, Kymera Therapeutics' Net Cash Flow (Quarterly) stood at -$104.3 million in 2021, then increased by 16.36% to -$87.2 million in 2022, then skyrocketed by 133.16% to $28.9 million in 2023, then tumbled by 66.99% to $9.5 million in 2024, then slumped by 617.79% to -$222.9 million in 2025.
  • Its Net Cash Flow was -$222.9 million in Q3 2025, compared to $245.9 million in Q2 2025 and -$30.3 million in Q1 2025.